While patient stratification might not be necessary in GISTs due to a high co-expression rate, exploring diagnostics approaches could be beneficial for other tumor types, such as soft-tissue sarcomas, melanoma, and ovarian carcinoma, where PDE3A expression is less frequent [10–12]. This evidence concerns the gene PDE3A and soft tissue sarcoma.